#Hypertension Drugs Market

[acumenblog]

Hypertension Drugs Market Size Surpasses USD 38.3 Billion by 2032 with a Robust 4.2% CAGR

Acumen Research and Consulting has recently published a research report on the Hypertension Drugs Market for the forecast period of 2023 – 2032, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Hypertension Drugs Market offers an extensive analysis of how the postoperative pain therapeutics landscape would evolve through…

[healthcareporium]

The recent approval of WINREVAIR for the treatment of Pulmonary Arterial Hypertension (PAH) marks a significant milestone in Merck's portfolio and the broader PAH market.

[macgyvermedical]

Hypertension (High Blood Pressure)

Did you know that almost 50% of people over the age of 18 have blood pressure higher than the currently recommended 130/80?

Did you know that by the age of 60, that number rises to 75%?

I used to believe this was because we had over-pathologized blood pressure. Surely something that 75% of people will experience in their lifetime is... just normal. Surely we could set the cutoff higher to more accurately capture truly pathological high blood pressures, decreasing the need for doctor visits and drugs.

But having thought about it, I think we actually may have found a cheat code instead of a pathology. Because I think the data is right- lower blood pressures put people at lower risk for heart disease and stroke.

But the numbers would indicate most of us don't naturally have low enough blood pressures to get this effect.

And today we have really decent drugs that can artificially lower blood pressure, thus conferring that added protection.

So I think if we marketed it as a cheat code instead of a treatment for disease, a lot more people would be willing to use it.

Just a thought.

[darkmaga-returns]

A Midwestern Doctor has written another expose on a critical topic, one which affects hundreds of millions of people. What is the truth about “high blood pressure?”

The link to AMD’s original article is at the end. I have copied the article here with the exception of the embedded video, which didn’t copy. Please use the link to view it.

By A Midwestern Doctor:

Story at a Glance:

High blood pressure (hypertension) is increasingly common, with more people diagnosed each decade.

This is because the threshold for “high” blood pressure keeps getting lowered—despite no evidence existing that those levels reduce deaths.

Excessively low blood pressure carries significant risk. Likewise, many of the blood pressure medications have common and significant side effects doctors often don’t recognize.

In this article we will review the key aspects of each common blood pressure lowering medication and healthier ways to address elevated blood pressures.

Frequently, when you dig into medical myths, you discover that many of the dogmas that underlie a popular drug are actually sales slogans a marketing company created. For instance, cholesterol lowering statins are widely prescribed despite the fact lowering cholesterol does not prevent heart disease (in fact cholesterol protects you, so when it’s low, you more likely to die), statins don’t prevent death, and these drugs harm 20% of users (often severely).

In turn, since so many people have been severely harmed by The Great Statin Scam, more and more public figures, such as comedian Jimmy Dore and Robert F. Kennedy Jr. have begun to speak out against this.

Sadly, statins are not the only mass-prescribed drug that’s marketed on deceptive premises and frequently makes the problem it “treats” worse. For example:

•A chemical imbalance from low serotonin was never linked to depression (in fact patients who commit suicide are found to have elevated brain serotonin). •Acid reflux is due to too little acid in the stomach (as acidity gives the stomach’s opening the signal to close). However, in medical school, we are always taught it is due to too much acidity. •"Sleeping" pills are actually sedatives that block the restorative phase of the sleep cycle.

Each of these drugs in turn is immensely harmful to their users, but due to how effectively their myths were established (just like “safe and effective”) they continue to be used by large numbers of people and harm them.

In turn, when you look into blood pressure, a similar pattern emerges. As I showed in the first part of this series there are two huge issues with this:

[transgenderer]

The Cheese Effect in MAOIs

A number of other MAOIs followed iproniazid onto the market, of which the best known were phenelzine and tranylcypromine. In 1961 there was a report in the Lancet of a patient who had a fatal subarachnoid hemorrhage while taking tranylcypromine. Subarachnoid hemorrhages are uncommon but occur frequently enough to make it al but impossible on the basis of a single case to implicate a drug that someone might have been taking. Reporting such a case in a journal like the Lancet, however, indicates a certain degree of suspicion on the part of the clinicians involved. This was one of seven such cases reported between 1961 and 1963. Some were fatal, but in those instances the subjects were taking more than one drug, making it impossible to finger tranylcypromine.

It also seemed that primary care physicians were noticing an increased occurrence of headaches in patients taking MAOIs. Examination of such patients suggested that some had blood pressure elevations, which could potentially tie in with the subarachnoid hemorrhages. Barry Blackwell, a psychiatric trainee at the Maudsley, drew attention to the possibility in a letter to the Lancet, which caught the eye of a hospital pharmacist in Nottingham named Rowe. He wrote to Blackwell detailing the occurrence of headache and hypertension in his wife, who had been taking a MOAI, after she ate cheese. Could there be something in cheese which cause a problem for people on these drugs? Blackwell and his colleagues were amused at the suggestion and dismissed it, not knowing that some of the American clinical trialists for tranylcypromine had noted headaches as a side effect. Max Lurie even suspected an interaction with the food that people were eating.

Gerald Samuel, working with one of the manfuacturers of an MAOI at the time, was less skeptical than the Maudsley doctors because the company had received two other suggestions of a similar nature. His remarks encouraged Blackwell and a colleague to take tranylcypromine for a week and then have cheese--nothing happened. The notion might have died at that point but that weekend Blackwell was called to see a lady who had taken phenelzine and had developed headache and hypertension--after a cheese sandwich. A patient in the hospital taking tranylcypromine agreed to take cheese with lunch and several hours later developed the increasingly familiar symptoms, as did two other patients in the hospital the afternoon after cheese made its weekly appearance on the dinner menu.

...

The medical profession only began to take the observations seriously when a scientific account could be given for what was happening. Ultimate it was shown that cheese contained tyramine, which appeared in the bloodstream after it was eaten. This could indeed increase blood pressure. The implicated was that the inhibit of monoamine oxidase in the wall of the guy allowed more tyramine than usual to enter the blood stream and hence the problem. The "cheese effect" was born. A variety of other foods were then shown to be problematic as well, including both wine and beer, beans, and other vegetables.

The Antidepressant Era, Healy

[the-empress-7]

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.

The most potent are members of the genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera.

Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of LSD, mescaline, and DMT.

In general, the effects include euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks.

In Mesoamerica, the mushrooms had long been consumed in spiritual and divinatory ceremonies before Spanish chroniclers first documented their use in the sixteenth century. In 1959, the Swiss chemist Albert Hofmann isolated the active principle psilocybin from the mushroom Psilocybe mexicana.

Hofmann's employer Sandoz marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic psychotherapy. Although the increasingly restrictive drug laws of the late 1960s curbed scientific research into the effects of psilocybin and other hallucinogens, its popularity as an entheogen (spirituality-enhancing agent) grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms.

The intensity and duration of the effects of psilocybin are variable, depending on species or cultivar of mushrooms, dosage, individual physiology, and set and setting, as was shown in experiments led by Timothy Leary at Harvard University in the early 1960s. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. The mind-altering effects of psilocybin typically last from two to six hours, although to individuals under the influence of psilocybin, the effects may seem to last much longer, since the drug can distort the perception of time. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and it has been classified as a scheduled drug by many national drug laws.

Leary and colleagues proposed that psilocybin heightens suggestibility, making an individual more receptive to interpersonal interactions and environmental stimuli. After ingesting psilocybin, a wide range of subjective effects may be experienced: feelings of disorientation, lethargy, giddiness, euphoria, joy, and depression. Volunteers given a high dose reported feelings of significant fear and 17% experienced transient paranoia. A 2011 prospective study by Roland R. Griffiths and colleagues suggests that a single high dosage of psilocybin can cause long-term changes in the personality of its users.

Common responses include pupil dilation (93%); changes in heart rate (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in blood pressure (84%), including hypotension (34%), hypertension (28%), and general instability (22%); changes in stretch reflex (86%), including increases (80%) and decreases (6%); nausea (44%); tremor (25%); and dysmetria (16%) (inability to properly direct or limit motions).

Most of the comparatively few fatal incidents reported in the literature that are associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially alcohol. Probably the most common cause of hospital admissions resulting from psychedelic mushroom usage involve "bad trips" or panic reactions, in which affected individuals become extremely anxious, confused, agitated, or disoriented. Accidents, self-injury, or suicide attempts can result from serious cases of acute psychotic episodes. Although no studies have linked psilocybin with birth defects, it is recommended that pregnant women avoid its usage.

Panic reactions can occur after consumption of psilocybin-containing mushrooms, especially if the ingestion is accidental or otherwise unexpected. Reactions characterized by violent behavior, suicidal thoughts, schizophrenia-like psychosis, and convulsions have been reported in the literature. A 2005 survey conducted in the United Kingdom found that almost a quarter of those who had used psilocybin mushrooms in the past year had experienced a panic attack. Other adverse effects less frequently reported include paranoia, confusion, prolonged derealization (disconnection from reality), and mania. Psilocybin usage can temporarily induce a state of depersonalization disorder. Usage by those with schizophrenia can induce acute psychotic states requiring hospitalization.

Well, this certainly explains a few things. Paranoia you say?

[sanskruti01]

Generative AI in Healthcare Market to Grow at an 35.1% CAGR Till 2032!

The global Generative AI in Healthcare Market worth USD 1.07 billion in 2023 is likely to be USD 21.74 billion by 2032, growing at a 35.1% CAGR between 2023 and 2032.

According to the stats published by World Health Organization (WHO), approximately 1.28 million adults (between 30 and 79 years of age) have hypertension. Of these, as little as 42% of adults are diagnosed and treated correctly and the remaining population is unaware of this condition. The majority of this population resides in low to middle-income countries of the world. Despite this substantial number of untreated cases, the rising awareness among doctors and the general population regarding health illnesses associated with hypertension is expected to drive the demand for the required devices.

Download White Paper@ https://www.towardshealthcare.com/personalized-scope/5069

A recent report provides crucial insights along with application based and forecast information in the Global Generative AI in Healthcare Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this Market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Generative AI in Healthcare Market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the Market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Report Objectives

To define, describe, and forecast the global Generative AI in Healthcare Market based on product, and region

To provide detailed information regarding the major factors influencing the growth of the Market (drivers, opportunities, and industry-specific challenges)

To strategically analyze microMarkets1 with respect to individual growth trends, future prospects, and contributions to the total Market

To analyze opportunities in the Market for stakeholders and provide details of the competitive landscape for Market leaders

To forecast the size of Market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, Market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Generative AI in Healthcare Market

Companies and Manufacturers Covered

The study covers key players operating in the Market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Generative AI in Healthcare Market are included as given below:

Generative AI in Healthcare Market Key Players:

Syntegra

NioyaTech

Saxon

IBM Watson

Microsoft Corporation

Google LLC

Tencent Holdings Ltd.

Neuralink Corporation

OpenAI

Oracle

Market Segments :

By Application

Clinical

Cardiovascular

Dermatology

Infectious Disease

Oncology

Others

System

Disease Diagnosis

Telemedicine

Electronic Health Records

Drug Interaction

By Function

AI-Assisted Robotic Surgery

Virtual Nursing Assistants

Aid Clinical Judgment/Diagnosis

Workflow & Administrative Tasks

Image Analysis

By End User

Hospitals & Clinics

Clinical Research

Healthcare Organizations

Diagnostic Centers

Others

By Geography

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

Contact US -

Towards Healthcare

Web: https://www.towardshealthcare.com/

You can place an order or ask any questions, please feel free to contact at 

Email:  sales@towardshealthcare.com

About Us

We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

[elyscape]

Pharmaceuticals really are a good example of this. If you go digging, you’ll find that the mechanism of action for nearly every single drug ever discovered fits neatly into one of the following categories:

Naligafen inhibits the MAT enzymes, which (among many other things) convert androhychoric acid to torimexone R3. TMR3 is converted by various other enzymes into torimexins, which cause inflammation, and algenton, which acts as the neurotransmitter for pain signals. By limiting the production of TMR3 in this way, naligafen relieves pain and inflammation.

Salphenorixine seems to cause blood serum levels of tyrentizone to increase and glucoramide to decrease. Given that higher levels of tyrentizone are associated with decreased blood pressure levels, and lower levels of glucoramide are associated with improved cardiovascular health, salphenorixine is recommended for hypertensive patients with a family history of heart conditions.

Tropalin is synthetic tropaldolin, which is the hormone that stimulates the release of stomach acid. In patients with acute achlorhydria, tropalin is administered to force the body to actually digest the contents of the stomach.

Clomatoxeplase fixes fingernail misalignment with no known side effects. Despite 50 years of intense research, its mechanism of action remains completely unknown.

Maxotox is a potent neurotoxin produced by the bacterium Pseudonomia maximilium that blocks chromium-channel signaling. When a sub-lethal dose is injected into the interplexular nerve, which connects the second and third ribs, it blocks the signal that causes hiccups.

Amphoric acid is not actually an acid or, for that matter, even medicine. It’s sugar water sold by scammers, but it occasionally kinda works because of the placebo effect. It has been banned from sale in Canada, India, the European Union, and New Zealand, but still sees heavy sales in the United States, Australia, and Brazil. Black market imports are an ongoing problem in Spain and the Netherlands.

Technology really is magic. I know that’s said a lot but like I’m sitting here looking at one of those chargers that you put your phone on top to wirelessly charge. And today is the first time I’ve really looked at it and gone “truly how the fuck does this work”

Maybe we stress about fantasy worldbuilding too much. We’re like “oh we gotta know the rules of the magic system,” no you don’t. I don’t know the rules of our magic system. If Aragorn, son of Arathorn got hit by a truck that orcs and goblins were driving flintstone style, and he transmigrated into my living room, I would not be able to explain any of the technology around me. I have no idea how I’m making this post. Imagine the first caveman who was like “oh shit the wheel” and I’m nodding along with that cave man. I understand how the wheel can roll. This next sentence was supposed to be about how I can sort of grasp how landline telephones work, but then I thought about it and no I don’t. I am surrounded everyday by mystical forces.

Anyway I have to use this particular charger because this miracle machine’s charging port is fuckin broken again

[snehalblog]

Global Phosphodiesterase Inhibitors Market: Key Trends, Drivers, and Challenges Shaping the Industry Landscape - UnivDatos

According to a new report by UnivDatos Market Insights, the Phosphodiesterase (PDE) Inhibitors Market, is expected to reach USD 4.58 Billion in 2030 by growing at a CAGR of 6.1%. Phosphodiesterase (PDE) Inhibitors are being used in healthcare organizations in various domains of cardiovascular, pulmonary, and urinary diseases. Phosphodiesterase (PDE) Inhibitors have a major application in treating erectile dysfunction. They act to block the enzyme phosphodiesterase, thus preventing the breakdown of important second messengers- cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP). Several factors are responsible for leading this market, prominently the rise in cases of chronic diseases, the rise in geriatric population, increased sedentary lifestyle, pharmaceutical investments, and a higher rate of obesity cases. The Consensus of Taiwan Society of Cardiology in May 2023 reported a prevalence of around 1-2% of heart failure in adults. The Centre for Disease Control and Prevention of the U.S. estimated that approximately 0.8 million people in the U.S. suffer from heart attack every year in May 2023.

Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=47356&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

The report suggests that the Rise in demand for Phosphodiesterase (PDE) 5 Inhibitors is one of the major factors driving the growth of phosphodiesterase (PDE) inhibitors in the market. PDE 5 inhibitors find most use in cases of pulmonary hypertension and erectile dysfunction. They initiate vasodilation in the lung and penis by blocking the breakdown of cyclic guanosine monophosphate (cGMP).  Four PDE5 inhibitors are FDA approved- sildenafil, vardenafil, tadalafil, and a recently approved drug avanafil among which sildenafil (Viagra, Pfizer), vardenafil (Levitra and Staxyn, Bayer/GlaxoSmithKline), tadalafil (Cialis, Eli Lilly), and avanafil (Stendra, Vivus) are commercially available in the U.S. PDE 5 inhibitors are safe to use and provide a better quality of life to patients. For instance, a study appeared in the Journal of Sexual Medicine in 2023 which indicates that the men exposed to PDE-5 had a 39% lower risk of dying due to cardiovascular-related diseases.

Apart from this, growing investment by governments in spreading awareness about chronic pulmonary and cardiovascular diseases will also have a positive impact on the phosphodiesterase (PDE) inhibitors market growth during the forecast period. Another prevalence seen in the phosphodiesterase (PDE) inhibitors market is collaborations between pharmaceutical organizations to promote the production of innovative PDE-5 inhibitors and to spread awareness about such chronic diseases. Reportedly, Dr. Reddy and Sunil Gavaskar collaborated in August 2023 for the “TensionMatLo” campaign to raise awareness about blood pressure control, for individuals who are currently suffering from hypertension and also for those who are at risk of acquiring this disease. Also, Lupin signed memorandum of understanding with the Government of Maharashtra, India to fight against cardiovascular diseases in June 2023.

PDE 5 Inhibitors Leading the Pharmaceutical Industry

Phosphodiesterase (PDE) inhibitors are currently leading the pharmaceutical industry due to their engagement in treating life-threatening cardiovascular and pulmonary diseases. Here are some key points to understand why phosphodiesterase (PDE) inhibitors are gaining momentum in the pharmaceutical market:

Effective FDA-approved Drugs: Several PDE 5 inhibitors are being approved by FDA for commercial sale and consumption. These drugs are efficient in action and safer to use which is the propelling factor for them in the market.

Patient Survival and Quality of Life: Because they are often more precisely directed at patient care, phosphodiesterase (PDE) inhibitors may offer improved survival rates and better quality of life for patients.

Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=47356&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Conclusion

The global phosphodiesterase (PDE) inhibitors market is a rapidly growing field, with advancements in health care and treatments leading to improved outcomes for patients. Phosphodiesterase (PDE) Inhibitors are a kind of drug type that is most frequently used in healthcare facilities. The global phosphodiesterase (PDE) inhibitors market is expected to continue to grow in the coming years, as new drugs are continuously being designed to improve patient outcomes. As a result, there is a growing demand for phosphodiesterase (PDE) inhibitors all over the world. Overall, the global phosphodiesterase (PDE) inhibitors market represents a significant opportunity for companies and professionals in the field of pharmaceuticals. With continued research and development, it is likely that even more effective and safer options for latex gloves will become available in the future, leading to improved outcomes for patients and healthcare professionals.Report this article

[neorangichealthcare]

PCD Pharma Franchise Opportunity in Pune

Are you looking to step into the pharmaceutical industry? If yes, the PCD Pharma Franchise model offers a golden opportunity. Pune, often referred to as the "Oxford of the East," is rapidly growing in terms of population and healthcare needs. This city is not just about IT parks and educational institutions; it's also emerging as a major hub for healthcare services.

Understanding PCD Pharma Franchise

Definition and Concept

A PCD Pharma Franchise is a partnership model where a pharmaceutical company grants the rights to distribute its products in a specific region. This business model allows entrepreneurs to leverage the company’s established brand and product portfolio.

Benefits of Owning a PCD Pharma Franchise

Low Investment: Compared to starting your own pharma company, a franchise requires significantly lower capital.

Monopoly Rights: You get exclusive rights to operate in your chosen area, reducing competition.

Extensive Support: Pharma companies often provide marketing materials, product training, and promotional support.

Why Choose Pune for Your Pharma Franchise?

Overview of Pune’s Healthcare Market

Pune’s healthcare sector is booming, thanks to its growing population and influx of professionals. With numerous hospitals, clinics, and pharmacies, the demand for quality medicines is at an all-time high.

Increasing Demand for Quality Healthcare Products

As awareness about health and wellness grows, people are seeking better pharmaceutical solutions. This makes Pune an attractive market for pharma entrepreneurs.

Strategic Location and Connectivity

Pune’s excellent connectivity to major cities like Mumbai and Bangalore ensures smooth logistics and supply chain management.

How to Start a PCD Pharma Franchise in Pune

Research and Market Analysis

Understanding the local healthcare needs and competitors is crucial before diving in.

Choosing the Right Pharma Company

Partner with a reputed company like Neorangic Healthcare to ensure high-quality products and strong support.

Documentation and Licensing Requirements

Ensure you have all necessary licenses, such as Drug License Number (DLN) and Goods and Services Tax (GST) registration.

Investment and Financial Planning

Estimate your initial and ongoing costs to avoid financial hiccups.

Key Features of a Successful Pharma Franchise

High-Quality Products

Quality is non-negotiable in the pharma industry. Ensure the company you partner with follows strict quality standards.

Strong Marketing and Distribution Network

Effective marketing strategies and a reliable distribution system are vital for success.

Comprehensive Training and Support

Look for companies that provide training and promotional materials to help you grow.

Top Pharma Products in Demand in Pune

Categories of Medicines to Focus On

General Medicines: High demand in local pharmacies.

Specialty Drugs: For chronic conditions like diabetes and hypertension.

Nutraceuticals and Supplements: Growing awareness about preventive healthcare is driving demand.

Challenges in Running a PCD Pharma Franchise

Competition in the Pharma Market

With numerous players in the market, standing out can be tough.

Managing Inventory and Distribution

Efficient inventory management is critical to avoid shortages or overstocking.

Adhering to Regulatory Compliance

Strict regulations can be challenging but are essential to maintain credibility.

How to Overcome Challenges in Pune

Strategic Marketing and Promotions

Invest in digital marketing, doctor tie-ups, and promotional campaigns.

Building Strong Relationships with Healthcare Providers

Establishing trust with doctors and pharmacists can significantly boost your sales.

Benefits of Partnering with Neorangic Healthcare

About Neorangic Healthcare

Neorangic Healthcare is a leading name in the pharmaceutical industry, known for its innovative and high-quality products.

Why Neorangic is the Best Choice for PCD Pharma Franchise in Pune

Extensive product portfolio.

Competitive pricing.

Comprehensive marketing support.

Conclusion

The PCD Pharma Franchise in Pune model is a lucrative business opportunity, especially in a growing city like Pune. You can build a successful and profitable venture with the right planning and a reliable partner like Neorangic Healthcare.

FAQs

What is the investment required for a PCD Pharma Franchise in Pune? The investment varies depending on the product range and company but generally starts from ₹50,000 to ₹2,00,000.

How do monopoly rights work in a PCD Pharma Franchise? Monopoly rights allow you to operate exclusively in a specific area, minimizing competition.

What support can I expect from Neorangic Healthcare? Neorangic Healthcare provides marketing materials, product training, and promotional support.

How profitable is the PCD Pharma Franchise business in Pune? With Pune’s growing demand for healthcare products, the profit potential is significant.

What documents are needed to start a PCD Pharma Franchise? You need a Drug License Number (DLN), GST registration, and other relevant certifications.

[medspotpk]

Comprehensive Guide to Geriatric Medicine and Specialty Drug Prices in Pakistan: Insights from Medspotpk

Healthcare costs are a significant concern for individuals and families across Pakistan, particularly when it comes to managing chronic conditions and advanced medical treatments. Medspotpk is a trusted platform providing detailed information about the latest prices of a variety of geriatric medicines and specialty drugs. In this blog, we will explore the current prices of geriatric medicine in Pakistan, including popular medications such as Dostinex 0.5 mg, Rhophylac 300 mg injection, Xtandi 40 mg, and Jardiance 10 mg.

Geriatric Medicine Price in Pakistan: Managing Health for Senior Citizens

Geriatric medicine focuses on the health and well-being of elderly individuals. As Pakistan's aging population grows, the demand for specific medications tailored to the needs of older adults has surged. These medications are designed to treat chronic conditions, improve quality of life, and manage symptoms related to aging.

Medspotpk provides comprehensive insights into the price of various geriatric medicines available in Pakistan. These medicines play a crucial role in enhancing the health of senior citizens and include treatments for conditions like hypertension, diabetes, arthritis, heart disease, and neurological disorders.

Dostinex 0.5 mg Price in Pakistan

Dostinex, containing the active ingredient Cabergoline, is primarily used to treat hormonal disorders such as hyperprolactinemia. This condition affects individuals by causing excess production of prolactin, which can lead to infertility, decreased libido, and other complications. Dostinex is commonly prescribed to balance hormonal levels, and its price varies depending on location and pharmacy in Pakistan.

Dostinex 0.5 mg Price in Pakistan: Typically ranges between PKR 250-350 per tablet. However, prices may fluctuate depending on stock availability and location.

Rhophylac 300 mg Injection Price in Pakistan

Rhophylac is a medication used to prevent and treat conditions such as Hemolytic Disease of the Newborn (HDN) and immune thrombocytopenic purpura (ITP). It is a vital medicine for pregnant women and individuals undergoing medical treatments that affect the immune system.

Rhophylac 300 mg Injection Price in Pakistan: Generally ranges between PKR 5,000 to PKR 7,000 per dose, though this can vary based on pharmacy and region.

Xtandi 40 mg Price in Pakistan

Xtandi, known for its active ingredient Enzalutamide, is widely used in the treatment of prostate cancer. With its role in managing advanced stages of prostate cancer, it has become an essential medication in oncology care.

Xtandi 40 mg Price in Pakistan: Typically ranges from PKR 75,000 to PKR 85,000 per month, depending on availability and specific pharmacy pricing.

Jardiance 10 mg Price in Pakistan

Jardiance, a well-known medication for managing Type 2 diabetes, works by helping lower blood sugar levels and improving cardiovascular health. It is a popular option for patients looking to manage their diabetes effectively.

Jardiance 10 mg Price in Pakistan: Generally priced around PKR 1,500 to PKR 2,000 per 30 tablets, which may vary with pharmacy location and stock levels.

Factors Influencing Medicine Prices in Pakistan

Several factors influence the pricing of geriatric medicines and specialty drugs in Pakistan:

Manufacturing Costs: The cost of producing high-quality medications directly impacts their market price.

Demand and Supply: The availability of medications can significantly affect pricing, especially for imported specialty drugs.

Regulations: Government policies and pharmaceutical regulations may lead to price controls or adjustments.

Pharmacy Location: Urban areas tend to have different pricing compared to rural regions due to logistical and operational factors.

Inflation and Economic Conditions: Fluctuations in the economy can lead to changes in medicine prices over time.

Why Choose Medspotpk for Medicine Prices?

Medspotpk is a reliable source for comprehensive and up-to-date information about medication prices in Pakistan. Whether you’re looking for information on geriatric medicine prices in Pakistan or specialty drugs like Dostinex, Xtandi, and Jardiance, the platform offers detailed insights to assist patients, healthcare providers, and caregivers in making informed decisions.

Final Thoughts

Managing chronic and advanced medical conditions often requires access to a variety of specialty medications. Medspotpk helps simplify this process by providing transparent and reliable pricing information for medications like Dostinex 0.5 mg, Rhophylac 300 mg injection, Xtandi 40 mg, and Jardiance 10 mg in Pakistan. By staying informed, patients can ensure they receive the best possible treatment at reasonable prices.

[surbhijamdade]

Peripheral Artery Disease Market Report: Significant Growth Projected Through 2033

Peripheral Artery Disease Market Report: Significant Growth Projected Through 2033

Straits Research is pleased to announce the release of its comprehensive report on the global Peripheral Artery Disease (PAD) market. The peripheral artery disease market size was valued at USD 5.22 Billion in 2024. It is projected to reach from USD 5.66 Billion by 2025 to USD 10.75 Billion by 2033, growing at a CAGR of 8.35% during the forecast period (2025–2033).

Market Overview

Peripheral artery disease is characterized by the narrowing or blockage of arteries supplying blood to the limbs, primarily due to atherosclerosis. This condition affects over 200 million adults globally, highlighting an urgent need for effective treatment options and innovations in medical technology. The increasing prevalence of PAD, driven by an aging population and rising rates of chronic diseases such as diabetes and hypertension, is a key factor fueling market growth.

Request a Sample Report of Peripheral Artery Disease Market

Key Drivers of Market Growth

The growth of the PAD market is attributed to several factors:

Rising Prevalence of PAD: With an increasing number of individuals diagnosed with PAD, the demand for treatment options is surging.

Technological Advancements: Innovations in minimally invasive procedures and devices are enhancing treatment efficacy and patient outcomes.

Aging Population: The global demographic shift towards an older population is contributing to a higher incidence of PAD.

Improved Healthcare Infrastructure: Enhanced healthcare systems, particularly in developing regions, are facilitating better access to treatment.

Segmentation Analysis

The Peripheral Artery Disease market can be segmented based on type, treatment method, disease category, and end-user:

By Type:

Peripheral Angioplasty Balloons

Plaque Modification Devices

Peripheral Stents

Peripheral Catheters

Hemodynamic Flow Alteration Devices

Inferior Vena Cava (IVC) Filters

Peripheral Accessories

By Treatment:

Devices

Catheters

Plaque Modification Devices

Hemodynamic Flow Alteration Devices

Others

By Disease:

Lipid Lowering Drugs

Triple-H Therapy

Glucose Regulating Drugs

Blood Clot Preventing Drugs

Inotropes

Thrombolytic Agents

Anti-Inflammatory Agents

By End User:

Hospitals & Clinics

Ambulatory Surgical Clinics

Buy Peripheral Artery Disease Market Report here!

Key Developments in the Market

The report highlights several significant developments within the PAD market:

Major players are increasingly investing in research and development to innovate new treatments and devices.

Collaborations between healthcare providers and technology companies are leading to enhanced product offerings.

Regulatory approvals for advanced medical devices are expected to boost market growth.

Leading Players in the Peripheral Artery Disease Market

Straits Research identifies several top key players driving innovation and competition in the PAD market:

Abbott Laboratories

Cardinal Health, Inc.

Boston Scientific Corporation

Cook Medical

Becton Dickinson and Company

Terumo Corporation

Koninklijke Philips N.V.

AngioDynamics, Inc.

BIOTRONIK

B. Braun Melsungen AG

These companies are pivotal in shaping the future of PAD treatment through their commitment to quality and innovation.

Browse Full Report and TOC of Peripheral Artery Disease Market

Conclusion

The global Peripheral Artery Disease market is poised for substantial growth over the coming years. The combination of rising prevalence rates, technological advancements, and an aging population presents significant opportunities for stakeholders in this sector.For more detailed insights into the Peripheral Artery Disease market trends and forecasts, please refer to our full report or contact Straits Research directly.

About Straits Research

Straits Research is a leading provider of business intelligence, specializing in research, analytics, and advisory services aimed at delivering comprehensive insights through detailed reports. For further information or inquiries about this press release or our research services, please contact us at sales@straitsresearch.com or call +1 646 905 0080.

[darkmaga-returns]

Story at a Glance:

High blood pressure (hypertension) is increasingly common, with more people diagnosed each decade.

This is because the threshold for “high” blood pressure keeps getting lowered—despite no evidence existing that those levels reduce deaths.

Excessively low blood pressure carries significant risk. Likewise, many of the blood pressure medications have common and significant side effects doctors often don’t recognize.

In this article we will review the key aspects of each common blood pressure lowering medication and healthier ways to address elevated blood pressures.

Frequently, when you dig into medical myths, you discover that many of the dogmas that underlie a popular drug are actually sales slogans a marketing company created. For instance, cholesterol lowering statins are widely prescribed despite the fact lowering cholesterol does not prevent heart disease (in fact cholesterol protects you, so when it’s low, you more likely to die), statins don’t prevent death, and these drugs harm 20% of users (often severely).

In turn, since so many people have been severely harmed by The Great Statin Scam, more and more public figures, such as comedian Jimmy Dore and Robert F. Kennedy Jr. have begun to speak out against this:

[bizionictechnologies]

Medical Apps for Patients: Bridging the Gap Between Technology and Health

Just last year, the global market for medical apps for patients and other healthcare technologies was valued at $14.4 billion and is expected to grow at a compound annual growth rate (CAGR) of 18.2% from 2024 to 2030, according to a report by Grand View Research. This explosive growth highlights the increasing role of technology in healthcare and how mobile applications in the healthcare industry are becoming an essential part of managing health. These apps are not only helping patients monitor their conditions but also transforming the way they engage with healthcare providers, making healthcare more accessible, personalized, and efficient.

The Role of Medical Apps for Patients in Modern Healthcare

Healthcare apps for patients have become powerful tools, offering everything from basic health tracking to complex medical management. As smartphones and wearables have become more ubiquitous, so has the use of apps in health and wellness. Here are a few ways these apps are changing the landscape:

Health Monitoring and Tracking Patients now can engage in health monitoring and tracking from the comfort of their own home. With apps designed to track everything from blood pressure and glucose levels to physical activity and medication adherence, managing chronic conditions has never been easier. For patients with diabetes, hypertension, or heart disease, these apps serve as constant reminders and give them detailed insights into their health, helping them make informed decisions in real-time.

Telemedicine and Virtual Consultations Telemedicine apps allow patients to consult healthcare providers remotely, a service that has proven invaluable, particularly in rural or underserved areas. Through video calls, messaging, and even live symptom checkers, patients can receive professional medical advice without leaving their homes. This is especially helpful for those who may find it difficult to travel due to mobility issues or time constraints. These healthcare apps for doctors are also reducing the burden on healthcare systems by decreasing wait times and allowing doctors to see more patients.

Appointment Scheduling and Reminders Gone are the days of calling medical offices to schedule appointments. Today, patients can book appointments through medical apps at their convenience. These apps also send reminders about upcoming appointments or when it’s time to refill a prescription, ensuring that patients stay on top of their healthcare needs. This feature also helps healthcare providers manage their schedules more efficiently, minimizing missed appointments and cancellations.

Personalized Health Advice and Education Medical apps often feature tools that allow patients to access relevant health information tailored to their individual needs. For example, apps can provide advice on nutrition, fitness, mental health, and preventive care based on the user’s age, gender, medical history, and lifestyle. By educating patients about healthy habits and potential risks, these apps promote long-term wellness and preventative care.

Medication Management Managing multiple medications can be a challenge, especially for patients with chronic conditions. Healthcare mobile apps for patients help with medication management apps remind patients to take their medications at the right time and even notify them when a prescription is about to run out. Some apps also offer features like drug interaction checkers and pill identifiers, ensuring that patients stay informed and avoid any potentially harmful mistakes.

Improved Patient Engagement Mobile applications for health are also changing the way patients interact with their healthcare providers. Many apps now allow patients to access their medical records, review test results, and communicate directly with their doctors. This level of transparency and communication encourages patients to take an active role in their healthcare journey, fostering better engagement and better health outcomes.

Why Medical Apps Matter for Patients

The impact of medical apps goes beyond convenience. They help improve patient outcomes, enhance the efficiency of healthcare systems, and reduce the overall cost of healthcare. By giving patients access to immediate and accurate information, these apps empower individuals to take control of their health in a way that was once unimaginable.

Furthermore, the data collected by medical apps can be used to improve patient care. Doctors and healthcare providers can analyze the data from these apps to offer more personalized and timely interventions. This data can also assist in research, improving overall healthcare knowledge and treatments.

How Bizionic Custom App Development Can Help

While the benefits of medical apps are clear, the success of these tools relies heavily on their design and functionality. Custom app development is essential to create an app that meets the unique needs of both patients and healthcare providers.

This is where Bizionic’s custom app development services come into play. Bizionic specializes in building tailored medical apps that ensure seamless user experiences, security, and compliance with healthcare regulations. Whether you’re looking to develop a telemedicine platform, a health tracking app, or a medication reminder service, Bizionic can help bring your vision to life.

Bizionic’s team of developers takes the time to understand the specific needs of your target audience, ensuring that the mobile applications for health you create are intuitive, efficient, and effective. They leverage the latest technologies and best practices to deliver high-quality, scalable, and secure medical applications. By partnering with Bizionic for your custom app development, you ensure that your medical app ranks among the top medical apps for patients, meeting the highest standards and contributing to better health outcomes.

In conclusion, medical apps are bridging the gap between technology and health, offering patients unprecedented control over their healthcare. As this trend continues, partnering with experts like Bizionic for custom app development can ensure that your healthcare app stands out as one of the best medical applications, meeting the ever-evolving needs of the medical field.

[industrynewsupdates]

Medical Sensors Market Size, Share And Trends Analysis Report

The global medical sensors market size is expected to reach USD 142.2 billion by 2030, registering a CAGR of 19.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. it's upsurge in the number of patients afflicted with chronic conditions, such as diabetes and hypertension, is fueling the usage of monitoring as well therapeutic devices, thus boosting the market demand. 

The target population for this market is patients with chronic illnesses, as such conditions necessitate regular checkups and intermittent or continuous patient monitoring. The rise in population of chronically ill patients further increases the uptake of the medical sensors. 

The geriatric population is highly prone to developing chronic disorders and they pose a higher risk of developing age-related deformities and complications. Moreover, the adoption of unhealthy food habits and sedentary lifestyles and the resultant surge in the incidence of obesity has led to the increasing prevalence of lifestyle disorders including diabetes. The presence of a large target population base combined with the prevalence of lifestyle-related risk factors is likely to accelerate the growth of the medical sensors market during the forecast period. 

Gather more insights about the market drivers, restrains and growth of the Medical Sensors Market

Medical Sensors Market Report Highlights

• The biosensors products segment held a lucrative share of over 44.0% in 2023. This is ascribable to the following attributes of the novel biosensors: durability, reliability, and accuracy. Moreover, their applications in the healthcare areas, such as the detection of drug abuse, glucose monitoring for diabetes, the detection of cholesterol, and others. All these elements governed the growth of this segment in 2023. 

• The surgical applications of the sensors dominated the market in 2023. Whereas, the monitoring applications segment is projected to be the fastest growing during the forecast period. Advancements, such as wearable technology are anticipated to boost the demand for the monitoring devices market. 

• The hospitals registered a remunerative growth in 2023; this can be attributed to the presence of a well-developed healthcare infrastructure, which yields faster and accurate diagnosis. Moreover, the availability of well-equipped infrastructure coupled with the presence of skilled personnel and technologically advanced equipments contribute towards the lucrative growth of this segment. 

• North America held a considerably large share of over 34.6% in 2023 owing to the presence of leading sensor manufacturers, a well-planned medical reimbursement network, and the increasing disposable income 

• On the contrary, Asia Pacific is anticipated to be the fastest growing region with a CAGR of over 20.6% over the forecast period. The favorable economic developments and the advancing healthcare system with the aid of supportive government initiatives are anticipated to further assist the growth. Moreover, the increasing base of the aging population in this region also, additionally impels the demand. According to the report published by the Ministry of Statistics, in India, 8.6% of the total population is aged above 60; hence, presenting a profitable opportunity for the market players to invest in this region.

Medical Sensors Market Segmentation

Grand View Research has segmented the global medical sensors market based on product, application, end use, and region:

Medical Sensors Product Outlook (Revenue, USD Million, 2018 - 2030)

• Pressure Sensors

• Temperature Sensor

• Image Sensors

• Accelerometer

• Biosensors

o Cholesterol

o Blood Glucose

o Blood Gas Analyzers

o Pregnancy testing

o Drug Discovery

o Infectious Diseases

• Flow Sensors

• Squid Sensors

• Others

Medical Sensors Application Outlook (Revenue, USD Million, 2018 - 2030)

• Surgical

• Diagnostics

• Therapeutics

• Monitoring

Medical Sensors End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital

• Stand Alone clinics

• Nursing Homes

• Home Healthcare

• Others

Medical Sensors Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa (MEA)

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Medical Sensors Market Intelligence Study, published by Grand View Research.